Phibro Animal Health reports Q2 EPS 54c, consensus 45c

Reports Q2 revenue $309.3M, consensus $316.5M. “Phibro has achieved exceptional results this quarter, fueled by robust demand in our Animal Health segment and the successful integration of the Zoetis Medicated Feed Additive portfolio,” stated Jack Bendheim, CEO. “Our impressive 24% revenue growth and notable enhancement in profitability underscore the strength of our diverse product offerings, our commitment to operational excellence across all segments, and our dedication to delivering essential solutions to customers worldwide. The momentum we’ve established positions us favorably for the remainder of fiscal 2025 and beyond. We are optimistic about our capability to foster sustainable growth and create value through our Phibro Forward initiative, strategic investments in innovation, targeted portfolio expansion, and disciplined financial management. With our updated financial guidance, we reaffirm our commitment to strong performance and enhancing shareholder value. We are excited to include the new MFA portfolio in our guidance, which reflects our confidence in a seamless integration and strong performance alongside improving profitability in our legacy business.”